Richard Ding, CEO
Richard Ding has executive leadership experience in the biopharmaceutical and diagnostics industry. He was a member of the research team at Myriad Genetics that cloned the BRCA1 gene and developed BRCA, one of the first and most prominent genetic tests. Richard subsequently joined Eli Lilly and took various strategy and business development positions. In 2006, Richard joined bioMerieux as Senior VP, Strategy and Business Development. He became the founding CEO of bioTheranostics in 2008. Richard is a leader in the emerging personalized medicine field and has served as a board of director of several life science and diagnostic companies. Richard holds an MBA from the University of Utah and received his undergraduate education at Fudan University, China.
Gail A. Sloan, CPA, Chief Financial Officer
Gail Sloan has over 20 years of financial experience at publicly traded (NASDAQ) companies in the life sciences industry as well as 8 years with a Big 4 accounting firm. Prior to joining bioTheranostics, Gail held the Chief Financial Officer and VP Finance positions at La Jolla Pharmaceutical Co. (LJPC), a publicly traded biopharmaceutical company. During her 16 year tenure at LJPC, she played a key role in raising more than $330 million through multiple private placements and public offerings and was responsible for all finance activities including SEC reporting and compliance with Sarbanes-Oxley Act requirements. Previously, Gail was Assistant Controller at Affymax Research Institute (AFFY), a publicly traded drug discovery technology company, prior to its acquisition by Glaxo Wellcome in 1995. While at AFFY, Gail helped lead the spin out of Affymetrix Inc., (AFFX) a manufacturer of DNA microarrays. Gail started her finance career at the public accounting firm of Ernst & Young, LLP, where attained the position of Audit Manager. Gail is certified public accountant with the State of California and earned her B.S. in Business from California Polytechnic State University, San Luis Obispo.
Catherine Schnabel, PhD, Vice President Translational Science
Catherine Schnabel has over 15 years of experience as an industry scientist across pharmaceutical, clinical and diagnostics research, including positions with Genentech, Genoptix , and Amylin Pharmaceuticals. Joining bioTheranostics in 2009 she has led the translational science and strategic programs for clinical development of proprietary molecular diagnostics in oncology and genomic medicine. Dr. Schnabel received her PhD training in molecular and cellular biology at the Center for Advanced Biotechnology and Medicine, and was a postdoctoral fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University. Dr. Schnabel is an industry leader in the development of evidence-based diagnostics, and building clinical value for molecular tests. She is a named co-inventor on several patents and has authored numerous publications. As Vice President of Translational Science, Dr. Schnabel provides scientific leadership and continued oversight of clinical development, medical strategy and regulatory plans for bioTheranostics’ products.
Matt Sargent, MS, MBA, Vice President Sales
Matt Sargent has more than 16 years of life sciences experience, with a strong focus in molecular oncology diagnostics. He most recently was vice president of oncology sales for Caris Life Sciences, where he built and trained the oncology sales team, resulting in significant sales growth and market penetration of their molecular profiling and NGS product line. He has also held senior sales leadership positions at MedTrust Online, and Exiqon Diagnostics. Matt received a bachelor’s degree in anatomy and animal physiology from Cornell University, a master’s degree in cancer physiology from the State University of New York at Buffalo, and a master’s degree in business administration from Pepperdine University.
Lale White, Executive Chairman and CEO of Xifin, Inc.
Lale White is founder and CEO of XIFIN, Inc. XIFIN is the innovator and provider of a new accounts receivable and financial management application for the healthcare industry. Ms White is a nationally recognized expert in the field of medical financial management and regulatory compliance. She lectures and consults extensively on these topics to major laboratories and laboratory associations throughout the U.S.A She has over 20 years of successful executive leadership in financial management, information systems development and medical billing with several of the largest independent clinical reference laboratories where she held senior management positions. Prior to founding XIFIN, Ms. White was Vice President of Finance at Laboratory Corporation of America. She was also a principal contributor in working with HCFA and the U.S. Office Of The Inspector General to develop the current OIG Model Compliance Program. Lale holds an MBA degree in Finance from Florida International University.
Brian Armstrong, Chief Financial Officer of bioMérieux Inc.
Brian Armstrong is the Chief Financial Officer for bioMérieux Inc. Based in Durham, North Carolina, he is responsible for all financial aspects of the bioMérieux US operations. Brian has been with bioMérieux for 17 years. Prior to joining bioMérieux, he was Audit Senior Manager with Ernst & Young. He is a CPA and member of AICPA.
Brad Smith, former Vice Chairman of LabCorp
Brad Smith is a former Vice Chairman of LabCorp. He has extensive executive experience in operations, legal and corporate affairs within the diagnostics and clinical laboratory industry. He has also held various positions including Assistant Vice President Law and General Counsel with Roche Biomedical Laboratories.